朱永翔,张瑶俊,窦克非,蔡金赞,庞思,朱灏,陈绍良

• 1:南京医科大学附属南京医院(南京市第一医院)心血管内科
• 2:中国医学科学院阜外医院心内科
• 3:东南大学医学院

摘要(Abstract)：

<正>冠状动脉分叉病变作为经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)中的常见病变,占PCI总量的15%~20%~([1])。但由于其存在边支易闭塞、手术技术难度大、再狭窄风险高等问题,使之成为PCI最具挑战的病变之一。药物洗脱支架(drug eluting stents,DES)是目前治疗冠状动脉分叉病变的主要选择,但DES也并非完美,

关键词(KeyWords)： 生物可吸收支架;分叉病变;经皮冠状动脉介入治疗;光学相干断层成像

Abstract:

Keywords:

基金项目(Foundation): 南京市医学科技发展资金资助项目(YKK15100);; 南京市科技计划项目(201503024)

作者(Author): 朱永翔,张瑶俊,窦克非,蔡金赞,庞思,朱灏,陈绍良

参考文献(References)：

• [1]Lassen JF,Holm NR,Stankovic G,et al.Percutaneous coronary intervention for coronary bifurcation disease:consensus from the first 10 years of the European Bifurcation Club meetings.Euro Intervention,2014,10(5):545-560.
• [2]Latib A,Costopoulos C,Naganuma T,et al.Which patients could benefit the most from bioresorbable vascular scaffold implant:from clinical trials to clinical practice.Minerva Cardioangiol,2013,61(3):255-262.
• [3]Serruys PW,Chevalier B,Dudek D,et al.A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions(ABSORBⅡ):an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.Lancet,2015,385(9962):43-54.
• [4]Ellis SG,Kereiakes DJ,Metzger DC,et al.Everolimus-eluting bioresorbable scaffolds for coronary artery disease.N Engl J Med,2015,373(20):1905-1915.
• [5]Kimura T,Kozuma K,Tanabe K,et al.A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs.everolimus-eluting metallic stents in patients with coronary artery disease:ABSORB Japan.Eur Heart J,2015,36(47):3332-3342.
• [6]Gao R,Yang Y,Han Y,et al Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease:ABSORB China trial.J Am Coll Cardiol,2015,66(21):2298-2309.
• [7]庞思,潘道蓉,朱灏,等.生物可吸收支架与钴铬合金依维莫司洗脱支架治疗冠心病的Meta分析.中国循环杂志,2016,31(1):15-19.
• [8]周力,孙颖,陈晖.全吸收式生物可降解支架在冠心病介入治疗中的应用.中国介入心脏病学杂志,2014,22(4):262-264.
• [9]Latib A,Capodanno D,Lesiak M,et al.Lessons from the GHOST-EU registry.Euro Intervention,2015,11 Suppl V:V170-V174.
• [10]Sgueglia GA,D'Errico F,GioffrèG,et al.First ad hoc bioresorbable vascular scaffold bench test:a glimpse into percutaneous bifurcation interventions.Int J Cardiol,2014,172(3):604-606.
• [11]D6avík V,Colombo A.The absorb bioresorbable vascular scaffold in coronary bifurcations:insights from bench testing.JACC Cardiovasc Interv,2014,7(1):81-88.
• [12]van Geuns RJ,Gogas BD,Farooq V,et al.3-Dimensional reconstruction of a bifurcation lesion with double wire after implantation of a second generation everolimus-eluting bioresorbable vascular scaffold.Int J Cardiol,2011,153(2):e43-e45.
• [13]Gogas BD,van Geuns RJ,Farooq V,et al.Three-dimensional reconstruction of the post-dilated ABSORB everolimus-eluting bioresorbable vascular scaffold in a true bifurcation lesion for flow restoration.JACC Cardiovasc Interv,2011,4(10):1149-1150.
• [14]Chen X,Zhang D,Yin D,et al.Can“true bifurcation lesion”actually be regarded as an independent risk factor of acute side branch occlusion after main vessel stenting?:A retrospective analysis of 1,200 consecutive bifurcation lesions in a single center.Catheter Cardiovasc Interv,2016,87 Suppl 1:554-563.
• [15]Romagnoli E,De Servi S,Tamburino C,et al.Real-world outcome of coronary bifurcation lesions in the drug-eluting stent era:results from the 4,314-patient Italian Society of Invasive Cardiology(SICI-GISE)Italian Multicenter Registry on Bifurcations(I-BIGIS).Am Heart J,2010,160(3):535-542.
• [16]Seth A,Sengottuvelu G,Ravisekar V.Salvage of side branch by provisional“TAP technique”using AbsorbTMbioresorbable vascular scaffolds for bifurcation lesions:first case reports with technical considerations.Catheter Cardiovasc Interv,2014,84(1):55-61.
• [17]Costopoulos C,Naganuma T,Latib A,et al.Optical coherence tomography of a bifurcation lesion treated with bioresorbable vascular scaffolds with the“mini-crush”technique.JACC Cardiovasc Interv,2013,6(12):1326-1327.
• [18]Sato K,Latib A,Panoulas VF,et al.A case of true left main bifurcation treated with bioresorbable everolimus-eluting stent vstenting.JACC Cardiovasc Interv,2014,7(8):e103-e104.
• [19]van Mieghem N,Wilschut JJ,Ligthart J,et al.Modified Ttechnique with bioresorbable scaffolds ensures complete carina coverage:an optical coherence tomography study.JACC Cardiovasc Interv,2014,7(8):e109-e110.
• [20]Dzavík V,Muramatsu T,Crooks N,et al.Complex bifurcation percutaneous coronary intervention with the Absorb bioresorbable vascular scaffold.Euro Intervention,2013,9(7):888.
• [21]Wiebe J,Hamm C,Nef H.A true bifurcational stenosis treated with a bioresorbable vascular scaffold and a drug-eluting metallic stent:Degradable meets durable.Catheter Cardiovasc Interv,2015,85(7):1184-1188.
• [22]Jim MH.No-kiss sleeve:a technical modification of the sleeve technique to treat true bifurcation lesions in the bioresorbable vascular scaffold era.Int J Cardiol,2014,176(2):532-534.
• [23]Grundeken MJ,Hassell ME,Kraak RP,et al.Treatment of coronary bifurcation lesions with the Absorb bioresorbable vascular scaffold in combination with the Tryton dedicated coronary bifurcation stent:evaluation using two-and threedimensional optical coherence tomography.Euro Intervention,2015,11(8):877-884.
• [24]Mc Geoch RJ,Tanaka K,Overgaard CB.Proximal optimization technique and kissing balloon inflations with the bioresorbable vascular scaffold for coronary bifurcation percutaneous coronary intervention.Can J Cardiol,2014,30(11):1461.e5-e7.
• [25]Prati F,Di Vito L,Biondi-Zoccai G,et al.Angiography alone versus angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention:the Centro per la Lotta contro lInfarto-Optimisation of Percutaneous Coronary Intervention(CLI-OPCI)study.Euro Intervention,2012,8(7):823-829.